DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Yigal Nochomovitz - 1 Olema - 1 Nochomovitz - 1 Palazestrant - 1 palazestrant - 1 ribociclib - 1
Top related locs:
Top related orgs:
Oncology - 1 Citi Research - 1 FDA - 1

Search resuls for: "Yigal Nochomovitz"


2 mentions found


☆ This little-known oncology stock could jump more than 70%, Citi says
  + stars: | 2024-01-30 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Olema Oncology could be a standout player in developing therapies for women's cancers, particularly in breast cancer, according to Citi Research. The stock was flat in trading on Tuesday, but has fallen more than 16% so far this year. Last year, Olema shares soared more than 470% as the company released a series of positive updates, particularly about its lead investigational oncology drug palazestrant , Nochomovitz said. "We believe palazestrant has emerged as a highly promising CERAN/SERD with opportunities across multiple lines of ER+ breast cancer," Nochomovitz wrote in a Tuesday note. CDK4/6 inhibitors are drugs that are used to treat metastatic breast cancer, or advanced stage IV breast cancer, which has spread to other organs in the body far from the breast.
Persons: Yigal Nochomovitz, Olema, Nochomovitz, Palazestrant, palazestrant, ribociclib Organizations: Oncology, Citi Research, FDA
☆ U.S. FDA staff flags unclear benefits of Ardelyx's kidney disease drug
  + stars: | 2022-11-14 | by ( ) www.reuters.com   time to read: +2 min
Nov 14 (Reuters) - U.S. Food and Drug Administration staff reviewers on Monday raised concerns over unclear benefits of Ardelyx Inc's (ARDX.O) drug for kidney disease patients, but the company's shares rose 20% on expectations over a possible approval. The FDA's staff reviewers said, "the magnitude of treatment effect appears less than that observed with approved drugs," in briefing documents released on Monday. Ardelyx's oral drug, tenapanor, is aimed at reducing elevated blood phosphate levels in patients with chronic kidney disease (CKD). The advisers' meeting, set for Nov.16, was called by the FDA following Ardelyx's appeal against the regulator's initial rejection of the drug in July last year, after it identified deficiencies. Around 37 million people, or one in seven people, in the United States have chronic kidney disease, as per a government report last year.
0 next >>
Total: 2